Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Cisplatin|DRUG: carboplatin
Sponsor: Massachusetts General Hospital
Collaborators: Beth Israel Deaconess Medical Center|Dana-Farber Cancer Institute|North Shore Medical Center